MedTrace Logo

PET Imaging of Systemic Sclerosis Using FDG and 68Ga-DOTA-Siglec-9

NCT05108857 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-12-04

No results posted yet for this study

Summary

This study evaluates the potential of positron emission tomography (PET)/computed tomography (CT) imaging to monitor disease activity in patients with systemic sclerosis (SSc). PET/CT imaging will focus on two pathological features of SSc, i.e. metabolic activity evaluated by glucose analog 18F-FDG, and expression of inflammation-inducible vascular adhesion protein 1 (VAP-1) evaluated by 68Ga-DOTA-Siglec-9 tracer.

Conditions

Sponsors & Collaborators

  • Kuopio University Hospital

    collaborator OTHER

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Anne Roivainen · Turku University Hospital, Turku PET Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05108857 on ClinicalTrials.gov